22.50Open22.50Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover1280.95%IV-466.34%PremiumJan 17, 2025Expiry Date36.91Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4684Delta0.0556Gamma0.08Leverage Ratio-0.1179Theta-0.0077Rho-0.04Eff Leverage0.0023Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet